1.81 USD
+0.07 (+4.02%)
1.84 USD
+0.03 (+1.66%)
Taking everything into account, OVID scores 3 out of 10 in our fundamental rating. OVID was compared to 525 industry peers in the Biotechnology industry. OVID scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. OVID is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year OVID has reported negative net income.
- In the past year OVID has reported a negative cash flow from operations.
- In the past 5 years OVID reported 4 times negative net income.
- OVID had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- OVID's Return On Assets of -56.90% is in line compared to the rest of the industry. OVID outperforms 44.19% of its industry peers.
- With a Return On Equity value of -81.28%, OVID perfoms like the industry average, outperforming 51.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -56.9% | ||
| ROE | -81.28% | ||
| ROIC | N/A |
ROA(3y)-33.31%
ROA(5y)-29.01%
ROE(3y)-46.44%
ROE(5y)-51.69%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- OVID does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- OVID does not have a ROIC to compare to the WACC, probably because it is not profitable.
- OVID has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for OVID has been increased compared to 5 years ago.
- There is no outstanding debt for OVID. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- OVID has an Altman-Z score of -4.82. This is a bad value and indicates that OVID is not financially healthy and even has some risk of bankruptcy.
- OVID has a worse Altman-Z score (-4.82) than 60.95% of its industry peers.
- OVID has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.82 |
ROIC/WACCN/A
WACC8.86%
2.3 Liquidity
- OVID has a Current Ratio of 4.24. This indicates that OVID is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of OVID (4.24) is comparable to the rest of the industry.
- A Quick Ratio of 4.24 indicates that OVID has no problem at all paying its short term obligations.
- With a Quick ratio value of 4.24, OVID perfoms like the industry average, outperforming 51.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.24 | ||
| Quick Ratio | 4.24 |
3. Growth
3.1 Past
- OVID shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.38%.
- The Revenue has grown by 946.55% in the past year. This is a very strong growth!
- Measured over the past years, OVID shows a very negative growth in Revenue. The Revenue has been decreasing by -86.05% on average per year.
EPS 1Y (TTM)-6.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15%
Revenue 1Y (TTM)946.55%
Revenue growth 3Y-86.05%
Revenue growth 5YN/A
Sales Q2Q%-23.7%
3.2 Future
- The Earnings Per Share is expected to decrease by -3.38% on average over the next years.
- Based on estimates for the next years, OVID will show a very strong growth in Revenue. The Revenue will grow by 63.21% on average per year.
EPS Next Y-30.82%
EPS Next 2Y-10.7%
EPS Next 3Y-12.9%
EPS Next 5Y-3.38%
Revenue Next Year892.86%
Revenue Next 2Y-49.61%
Revenue Next 3Y-47.73%
Revenue Next 5Y63.21%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for OVID. In the last year negative earnings were reported.
- Also next year OVID is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as OVID's earnings are expected to decrease with -12.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.7%
EPS Next 3Y-12.9%
5. Dividend
5.1 Amount
- OVID does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
OVID THERAPEUTICS INC / OVID FAQ
Can you provide the ChartMill fundamental rating for OVID THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 3 / 10 to OVID.
What is the valuation status of OVID THERAPEUTICS INC (OVID) stock?
ChartMill assigns a valuation rating of 0 / 10 to OVID THERAPEUTICS INC (OVID). This can be considered as Overvalued.
What is the profitability of OVID stock?
OVID THERAPEUTICS INC (OVID) has a profitability rating of 1 / 10.
What is the financial health of OVID THERAPEUTICS INC (OVID) stock?
The financial health rating of OVID THERAPEUTICS INC (OVID) is 6 / 10.
What is the earnings growth outlook for OVID THERAPEUTICS INC?
The Earnings per Share (EPS) of OVID THERAPEUTICS INC (OVID) is expected to decline by -30.82% in the next year.